JP2005519905A5 - - Google Patents

Download PDF

Info

Publication number
JP2005519905A5
JP2005519905A5 JP2003561574A JP2003561574A JP2005519905A5 JP 2005519905 A5 JP2005519905 A5 JP 2005519905A5 JP 2003561574 A JP2003561574 A JP 2003561574A JP 2003561574 A JP2003561574 A JP 2003561574A JP 2005519905 A5 JP2005519905 A5 JP 2005519905A5
Authority
JP
Japan
Prior art keywords
dna
pharmaceutical formulation
tucaresol
mpl
cpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003561574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519905A (ja
Filing date
Publication date
Priority claimed from GB0201735A external-priority patent/GB0201735D0/en
Priority claimed from GBGB0201736.6A external-priority patent/GB0201736D0/en
Application filed filed Critical
Priority claimed from PCT/GB2003/000336 external-priority patent/WO2003061629A2/en
Publication of JP2005519905A publication Critical patent/JP2005519905A/ja
Publication of JP2005519905A5 publication Critical patent/JP2005519905A5/ja
Pending legal-status Critical Current

Links

JP2003561574A 2002-01-25 2003-01-23 Dnaの製剤 Pending JP2005519905A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201735A GB0201735D0 (en) 2002-01-25 2002-01-25 DNA dosage forms
GBGB0201736.6A GB0201736D0 (en) 2002-01-25 2002-01-25 DNA dosage forms
PCT/GB2003/000336 WO2003061629A2 (en) 2002-01-25 2003-01-23 Dna dosage forms

Publications (2)

Publication Number Publication Date
JP2005519905A JP2005519905A (ja) 2005-07-07
JP2005519905A5 true JP2005519905A5 (cg-RX-API-DMAC10.html) 2006-02-09

Family

ID=27614803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003561574A Pending JP2005519905A (ja) 2002-01-25 2003-01-23 Dnaの製剤

Country Status (8)

Country Link
US (2) US20050085434A1 (cg-RX-API-DMAC10.html)
EP (1) EP1467711B1 (cg-RX-API-DMAC10.html)
JP (1) JP2005519905A (cg-RX-API-DMAC10.html)
AT (1) ATE357219T1 (cg-RX-API-DMAC10.html)
CA (1) CA2473717A1 (cg-RX-API-DMAC10.html)
DE (1) DE60312645T2 (cg-RX-API-DMAC10.html)
ES (1) ES2285087T3 (cg-RX-API-DMAC10.html)
WO (1) WO2003061629A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884083B2 (en) * 2002-08-12 2011-02-08 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
AU2002951692A0 (en) * 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5856790A (en) * 1989-06-26 1991-01-17 Agracetus, Inc. Particle-mediated transformation of animal somatic cells
DK28792D0 (da) * 1992-03-04 1992-03-04 Novo Nordisk As Nyt enzym
WO1994023738A1 (en) * 1993-04-19 1994-10-27 Medisorb Technologies International L.P. Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression
WO1995019799A1 (en) * 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
ATE252373T1 (de) * 1994-08-04 2003-11-15 Elan Drug Delivery Ltd Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung
JP4386965B2 (ja) * 1996-04-26 2009-12-16 メルク エンド カンパニー インコーポレーテッド Dnaワクチン製剤

Similar Documents

Publication Publication Date Title
JP2004529078A5 (cg-RX-API-DMAC10.html)
JP2004532810A5 (cg-RX-API-DMAC10.html)
JP2004515500A5 (cg-RX-API-DMAC10.html)
JP2001194792A5 (cg-RX-API-DMAC10.html)
JP2004525194A5 (cg-RX-API-DMAC10.html)
JP2006517944A5 (cg-RX-API-DMAC10.html)
RU2489151C3 (ru) Фармацевтическая комбинация, содержащая ингибитор sglt2
DE60038304D1 (de) Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
JP2001131087A5 (cg-RX-API-DMAC10.html)
JP2005526016A5 (cg-RX-API-DMAC10.html)
JP2005538045A5 (cg-RX-API-DMAC10.html)
JP2005511619A5 (cg-RX-API-DMAC10.html)
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
JP2004505922A5 (cg-RX-API-DMAC10.html)
JP2002022755A5 (cg-RX-API-DMAC10.html)
JP2006505391A5 (cg-RX-API-DMAC10.html)
JP2000141643A5 (cg-RX-API-DMAC10.html)
EP1476174A4 (en) PHARMACEUTICAL PREPARATION WITH PROPHYLACTIC EFFECTS ON LAMIVUDINE-RELATED REACTIONS AND PHARMACORESISTANCE, AND METHODS OF USING THE SAME
JP2005536763A5 (cg-RX-API-DMAC10.html)
JP2002275230A5 (cg-RX-API-DMAC10.html)
JP2004526429A5 (cg-RX-API-DMAC10.html)
Kelly et al. Pro-life, Anti-death Penalty?
FR2857591B1 (fr) Particules comprenant un principe actif sous forme de co-precipite
JP2005298393A5 (cg-RX-API-DMAC10.html)